Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Siegfried Holding AGXSWX:SFZN -0.14%86 EV-to-EBIT is 13.87 as of Jul. 26, 2026, which is 39% below its 10-year median of 22.87. GuruFocus rates XSWX:SFZN with a GF Score™ of 86/100 and a GF Value™ of CHF92.49 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 690 Drug Manufacturers companies, Siegfried Holding AG ranks better than 55.07% on this metric.
Siegfried Holding AG (XSWX:SFZN) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Siegfried Holding AG's Enterprise Value for the quarter that ended in Dec. 2025 was CHF3,164 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Siegfried Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF216 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Siegfried Holding AG EV-to-EBIT Related Terms
Siegfried Holding AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Siegfried Holding AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:SFZN vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Siegfried Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Siegfried Holding AG EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Siegfried Holding AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Siegfried Holding AG's EV-to-EBIT falls into.
Siegfried Holding AG's current Enterprise Value is CHF2,993 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Siegfried Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF216 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Siegfried Holding AG (XSWX:SFZN) has a EV-to-EBIT of 13.87 as of Jul. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Siegfried Holding AG and its competitors. This is 39% below median its historical median of 22.87. Over the past decade, Siegfried Holding AG's EV-to-EBIT has ranged from 11.36 to 50.46. According to the industry distribution chart, Siegfried Holding AG ranks #310 out of 690 companies in the Drug Manufacturers industry, placing it in the top 44.9%.
Is Siegfried Holding AG's EV-to-EBIT too high?
Siegfried Holding AG's current EV-to-EBIT of 13.87 is 39% below median its 10-year median of 22.87. Over the past 10 years, this metric has ranged from a low of 11.36 to a high of 50.46. The Drug Manufacturers industry median EV-to-EBIT is 15.42. Siegfried Holding AG's value of 13.87 is 10.1% below this industry median. Based on the distribution chart, Siegfried Holding AG ranks #310 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Siegfried Holding AG has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Siegfried Holding AG's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Siegfried Holding AG ranks #310 out of 690 companies for EV-to-EBIT. This puts Siegfried Holding AG in the upper half of its industry. The industry median EV-to-EBIT is 15.42. Siegfried Holding AG's value of 13.87 is 10.1% below this benchmark. Historically, Siegfried Holding AG's own EV-to-EBIT has ranged from 11.36 to 50.46 over the past decade. While the company's 10-year median is 22.87 vs. the industry median of 15.42, Siegfried Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.42, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Siegfried Holding AG's current EV-to-EBIT of 13.87 is 10.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Siegfried Holding AG and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Siegfried Holding AG's current EV-to-EBIT is 13.87, which is 39% below median its own 10-year median of 22.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Siegfried Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Siegfried Holding AG (XSWX:SFZN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF92.49, compared to a current price of CHF70.70 — trading 23.6% below its estimated fair value. The current EV-to-EBIT is 13.87, which is 39% below median its 10-year median of 22.87 and 10.1% below the Drug Manufacturers industry median of 15.42. Siegfried Holding AG's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Siegfried Holding AG (XSWX:SFZN), the current EV-to-EBIT is 13.87 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Siegfried Holding AG (XSWX:SFZN) Overvalued in 2026?
Based on GuruFocus' analysis, Siegfried Holding AG stock appears to be undervalued.
The current stock price of CHF70.70 is trading 23.6% below its estimated GF Value™ of CHF92.49.
GuruFocus considers Siegfried Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:SFZN:
EV-to-EBIT: 13.87 (39% below median its 10-year median of 22.87)
GF Value™: CHF92.49 vs. price of CHF70.70 (23.6% below fair value)
Industry Position: 10.1% below the Drug Manufacturers median (#310 of 690)
No single metric tells the full story. See the XSWX:SFZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Siegfried is a global contract development and manufacturing organization. It derives its revenue primarily from long-term supply agreements with biotechnology and pharmaceutical customers. Siegfried develops and manufactures active pharmaceutical ingredients, finished dosage forms (tablets, capsules, sterile vials, ampules, cartridges, and ointments), and viral vectors. The company provides these services throughout the entire drug lifecycle, including chemical and analytical development, pilot manufacturing, and commercial-scale manufacturing. Siegfried has a large global footprint with 13 production sites on three continents.
86GF Score
Get the complete analysis for XSWX:SFZN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SFZN has been successfully added to your 
